MX358518B - Anticuerpos anti - asic1 y usos de los mismos. - Google Patents
Anticuerpos anti - asic1 y usos de los mismos.Info
- Publication number
- MX358518B MX358518B MX2014008541A MX2014008541A MX358518B MX 358518 B MX358518 B MX 358518B MX 2014008541 A MX2014008541 A MX 2014008541A MX 2014008541 A MX2014008541 A MX 2014008541A MX 358518 B MX358518 B MX 358518B
- Authority
- MX
- Mexico
- Prior art keywords
- asic1
- antibodies
- cells expressing
- acid
- asic1 antibodies
- Prior art date
Links
- 101710099904 Acid-sensing ion channel 1 Proteins 0.000 abstract 3
- 102100021624 Acid-sensing ion channel 1 Human genes 0.000 abstract 3
- 101000754290 Homo sapiens Acid-sensing ion channel 1 Proteins 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 102000048484 human ASIC1 Human genes 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 238000011477 surgical intervention Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La presente invención se refiere a anticuerpos y fragmentos de unión a antígeno de los mismos que se unen específicamente a células que expresan el canal sensible a ácido 1 (ASIC1). Según ciertas realizaciones de la invención, los anticuerpos inhiben las corrientes iónicas mediadas por ASICI inducidas por ácido en células que expresan ASIC1 humano. Los anticuerpos de la invención son útiles para el tratamiento del dolor, incluyendo dolor asociado a intervención quirúrgica y diversas enfermedades y trastornos.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261592837P | 2012-01-31 | 2012-01-31 | |
US201261644038P | 2012-05-08 | 2012-05-08 | |
US201261692925P | 2012-08-24 | 2012-08-24 | |
PCT/US2013/023784 WO2013116296A1 (en) | 2012-01-31 | 2013-01-30 | Anti-asic1 antibodies and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2014008541A MX2014008541A (es) | 2014-10-24 |
MX358518B true MX358518B (es) | 2018-08-24 |
Family
ID=47666522
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2014008541A MX358518B (es) | 2012-01-31 | 2013-01-30 | Anticuerpos anti - asic1 y usos de los mismos. |
Country Status (33)
Country | Link |
---|---|
US (3) | US9150648B2 (es) |
EP (2) | EP2809681B1 (es) |
JP (1) | JP6302844B2 (es) |
KR (1) | KR102111941B1 (es) |
CN (1) | CN104093738B (es) |
AR (1) | AR089852A1 (es) |
AU (1) | AU2013215254B2 (es) |
CA (1) | CA2862332C (es) |
CL (1) | CL2014002019A1 (es) |
CO (1) | CO7020877A2 (es) |
CY (2) | CY1121368T1 (es) |
DK (2) | DK2809681T3 (es) |
EA (1) | EA028647B1 (es) |
ES (2) | ES2886123T3 (es) |
HK (1) | HK1199269A1 (es) |
HR (2) | HRP20211541T1 (es) |
HU (2) | HUE042531T2 (es) |
IL (2) | IL233410A0 (es) |
IN (1) | IN2014CN04645A (es) |
JO (1) | JO3547B1 (es) |
LT (2) | LT3453723T (es) |
MX (1) | MX358518B (es) |
MY (1) | MY168748A (es) |
NZ (1) | NZ626242A (es) |
PH (1) | PH12014501613B1 (es) |
PL (2) | PL2809681T3 (es) |
PT (2) | PT2809681T (es) |
RS (2) | RS62454B1 (es) |
SG (1) | SG11201403222UA (es) |
SI (2) | SI3453723T1 (es) |
TW (1) | TWI591073B (es) |
UY (1) | UY34603A (es) |
WO (1) | WO2013116296A1 (es) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ626242A (en) | 2012-01-31 | 2017-02-24 | Regeneron Pharma | Anti-asic1 antibodies and uses thereof |
CA2945498A1 (en) * | 2014-04-15 | 2015-10-22 | Sorrento Therapeutics, Inc. | Antibody therapeutics that bind wisp1 |
HUE050007T2 (hu) | 2014-05-16 | 2020-11-30 | Ablynx Nv | Immunglobulin variábilis domének |
CN105233286B (zh) * | 2015-09-10 | 2018-10-30 | 上海交通大学医学院 | 含酸敏感离子通道调控剂的制剂及其在治疗瘙痒中的用途 |
CN105713089B (zh) * | 2016-02-26 | 2019-08-06 | 上海科技大学 | 一种特异性抑制酸敏感离子通道i型的全人抗体 |
WO2018085441A1 (en) * | 2016-11-01 | 2018-05-11 | Berg Llc | Filamin b binding proteins and uses thereof |
MD3638698T2 (ro) * | 2018-01-26 | 2021-07-31 | Regeneron Pharma | Anticorpi anti-TMPRSS2 și fragmente de legare al antigenului |
EP3980456A4 (en) * | 2019-06-04 | 2023-01-18 | Shanghaitech University | AFFINITY MATURED ANTI-ASIC1A ANTIBODIES |
MX2022000325A (es) * | 2019-07-11 | 2022-03-25 | Memorial Sloan Kettering Cancer Center | Anticuerpos dirigidos contra dll3 y usos de los mismos. |
GB2600333A (en) * | 2019-07-23 | 2022-04-27 | Univ Shanghai Technology | ASICI channel antagonist antibody |
AU2020346886A1 (en) * | 2019-09-13 | 2022-04-14 | Memorial Hospital For Cancer And Allied Diseases | Anti-CD371 antibodies and uses thereof |
IL310700A (en) * | 2021-08-09 | 2024-04-01 | Merck Patent Gmbh | Proteins that uncouple cell-mediated tumor cytotoxicity from proinflammatory cytokine release |
CN118159558A (zh) * | 2021-09-02 | 2024-06-07 | 纪念斯隆-凯特琳癌症中心 | 抗dll3抗体和其用途 |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2759373B1 (fr) | 1997-02-11 | 2001-05-04 | Centre Nat Rech Scient | Nouveau canal cationique neuronal de mammifere sensible a l'acidite, son clonage et ses applications |
WO1999021981A1 (en) | 1997-10-29 | 1999-05-06 | Mcgill University | Dna encoding a human proton-gated ion channel and uses thereof |
US6287859B1 (en) | 1998-08-05 | 2001-09-11 | Centre National De La Recherche | Identification, functional expression and chromosal localization of a sustained human proton-gated cation channel |
CA2304494A1 (en) | 2000-04-20 | 2001-10-20 | Philippe Seguela | A novel heteromultimeric ion channel receptor and uses thereof |
US6635432B1 (en) | 2000-04-25 | 2003-10-21 | University Of Iowa Research Foundation | Peptide potentiation of acid-sensory ion channel in pain |
US7132505B1 (en) | 2001-05-10 | 2006-11-07 | Centre National De La Recherche Scientifique - Cnrs | Polypeptide inhibiting a proton-gated Na+ channel, a nucleic acid coding for such polypeptide and a method of manufacturing an ASIC1a channel blocker |
CA2352702A1 (en) * | 2001-07-18 | 2003-01-18 | Philippe Seguela | Novel human proton gated ion channel |
AR039067A1 (es) * | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
US20070197583A1 (en) | 2002-03-29 | 2007-08-23 | Welsh Michael J | Novel compositions and methods for modulation of the acid-sensing ion channel (ASIC) for the treatment of anxiety and drug addiction |
US20030186860A1 (en) | 2002-03-29 | 2003-10-02 | Welsh Michael J. | Novel compositions and methods for modulating the acid-sensing ion channel (ASIC) |
AU2003220525A1 (en) * | 2002-03-29 | 2003-10-20 | Abgenix, Inc. | Human monoclonal antibodies to interleukin-5 and methods and compositions comprising same |
WO2005025518A2 (en) * | 2003-09-11 | 2005-03-24 | The Uab Research Foundation | Inhibition of inward sodium currents in cancer |
WO2005074923A1 (en) | 2004-02-03 | 2005-08-18 | Agt Biosciences Limited | Methods and compositions |
JP2007530664A (ja) | 2004-03-30 | 2007-11-01 | ペインセプター ファーマ コーポレーション | ゲートイオンチャンネルを調節するための組成物及び方法 |
WO2005103081A2 (en) | 2004-04-20 | 2005-11-03 | Genmab A/S | Human monoclonal antibodies against cd20 |
US7192500B2 (en) | 2004-04-30 | 2007-03-20 | Kimberly-Clark Worldwide, Inc. | Process for making a garment including an absorbent assembly |
US8030442B2 (en) | 2004-09-16 | 2011-10-04 | Morehouse School Of Medicine | Treatment of injury to the brain by inhibition of acid sensing ion channels |
WO2006068953A2 (en) * | 2004-12-21 | 2006-06-29 | Astrazeneca Ab | Antibodies directed to angiopoietin-2 and uses thereof |
MX2007013304A (es) * | 2005-04-26 | 2007-12-13 | Pfizer | Anticuerpos de p-caderina. |
MX2008014804A (es) * | 2006-06-02 | 2009-01-27 | Regeneron Pharma | Anticuerpos de afinidad elevada a receptor de il-6 humano. |
EP2975057A1 (en) * | 2006-07-10 | 2016-01-20 | Fujita Health University | Novel anti-cd73 antibody |
EP2043650A2 (en) | 2006-07-14 | 2009-04-08 | Medical Research Council | Treatment for demyelinating disease |
RU2448979C2 (ru) | 2006-12-14 | 2012-04-27 | Ридженерон Фармасьютикалз, Инк. | Антитела человека к дельта-подобному лиганду-4 человека |
US7598039B2 (en) | 2007-01-30 | 2009-10-06 | Academia Sinica | Treatment of insulin resistance |
ATE483985T1 (de) | 2007-04-03 | 2010-10-15 | Ilegusavnid Genetics Resource | Mit panikstörungen assoziierte amilorid-sensitive natriumkanäle |
WO2008134659A2 (en) * | 2007-04-27 | 2008-11-06 | Zymogenetics, Inc. | Antagonists to il-17a, il-17f, and il-23p19 and methods of use |
US20110262395A1 (en) * | 2008-05-08 | 2011-10-27 | University Of Utah Research Foundation | Sensory receptors for chronic fatigue and pain and uses thereof |
US20090291150A1 (en) | 2008-05-21 | 2009-11-26 | University Of Iowa Research Foundation | Method and compositions for treating and preventing seizures by modulating acid-sensing ion channel activity |
FR2932091B1 (fr) | 2008-06-06 | 2012-12-28 | Centre Nat Rech Scient | Effets analgesiques de la toxine peptidique apetx2 |
DK2356270T3 (da) * | 2008-11-07 | 2016-12-12 | Fabrus Llc | Kombinatoriske antistofbiblioteker og anvendelser deraf |
JO3672B1 (ar) * | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
US8926976B2 (en) * | 2009-09-25 | 2015-01-06 | Xoma Technology Ltd. | Modulators |
GB0922434D0 (en) * | 2009-12-22 | 2010-02-03 | Ucb Pharma Sa | antibodies and fragments thereof |
CN102234316B (zh) * | 2010-05-07 | 2014-01-29 | 中国人民解放军军事医学科学院毒物药物研究所 | 具有增强酸感受离子通道1a电流作用的多肽及其用途 |
US9371383B2 (en) | 2012-01-31 | 2016-06-21 | Regeneron Pharmaceuticals, Inc. | Anti-ASIC1 antibodies and uses thereof |
NZ626242A (en) | 2012-01-31 | 2017-02-24 | Regeneron Pharma | Anti-asic1 antibodies and uses thereof |
-
2013
- 2013-01-30 NZ NZ626242A patent/NZ626242A/en unknown
- 2013-01-30 WO PCT/US2013/023784 patent/WO2013116296A1/en active Application Filing
- 2013-01-30 HR HRP20211541TT patent/HRP20211541T1/hr unknown
- 2013-01-30 EP EP13702876.7A patent/EP2809681B1/en active Active
- 2013-01-30 KR KR1020147020682A patent/KR102111941B1/ko active IP Right Grant
- 2013-01-30 US US13/753,836 patent/US9150648B2/en active Active
- 2013-01-30 PT PT13702876T patent/PT2809681T/pt unknown
- 2013-01-30 AR ARP130100280 patent/AR089852A1/es active IP Right Grant
- 2013-01-30 MX MX2014008541A patent/MX358518B/es active IP Right Grant
- 2013-01-30 JO JOP/2013/0036A patent/JO3547B1/ar active
- 2013-01-30 EP EP18201823.4A patent/EP3453723B1/en active Active
- 2013-01-30 HU HUE13702876A patent/HUE042531T2/hu unknown
- 2013-01-30 SI SI201331923T patent/SI3453723T1/sl unknown
- 2013-01-30 TW TW102103458A patent/TWI591073B/zh active
- 2013-01-30 AU AU2013215254A patent/AU2013215254B2/en active Active
- 2013-01-30 EA EA201491452A patent/EA028647B1/ru not_active IP Right Cessation
- 2013-01-30 IN IN4645CHN2014 patent/IN2014CN04645A/en unknown
- 2013-01-30 RS RS20211284A patent/RS62454B1/sr unknown
- 2013-01-30 HU HUE18201823A patent/HUE056335T2/hu unknown
- 2013-01-30 SG SG11201403222UA patent/SG11201403222UA/en unknown
- 2013-01-30 JP JP2014554950A patent/JP6302844B2/ja active Active
- 2013-01-30 DK DK13702876.7T patent/DK2809681T3/en active
- 2013-01-30 LT LTEP18201823.4T patent/LT3453723T/lt unknown
- 2013-01-30 PL PL13702876T patent/PL2809681T3/pl unknown
- 2013-01-30 PT PT182018234T patent/PT3453723T/pt unknown
- 2013-01-30 ES ES18201823T patent/ES2886123T3/es active Active
- 2013-01-30 MY MYPI2014001721A patent/MY168748A/en unknown
- 2013-01-30 LT LTEP13702876.7T patent/LT2809681T/lt unknown
- 2013-01-30 PL PL18201823T patent/PL3453723T3/pl unknown
- 2013-01-30 SI SI201331343T patent/SI2809681T1/sl unknown
- 2013-01-30 RS RS20190287A patent/RS58439B1/sr unknown
- 2013-01-30 ES ES13702876T patent/ES2707599T3/es active Active
- 2013-01-30 CA CA2862332A patent/CA2862332C/en active Active
- 2013-01-30 CN CN201380007553.3A patent/CN104093738B/zh active Active
- 2013-01-30 DK DK18201823.4T patent/DK3453723T3/da active
- 2013-01-31 UY UY34603A patent/UY34603A/es not_active Application Discontinuation
-
2014
- 2014-06-26 IL IL233410A patent/IL233410A0/en unknown
- 2014-07-11 PH PH12014501613A patent/PH12014501613B1/en unknown
- 2014-07-25 CO CO14162499A patent/CO7020877A2/es unknown
- 2014-07-30 CL CL2014002019A patent/CL2014002019A1/es unknown
- 2014-12-23 HK HK14112815.2A patent/HK1199269A1/xx unknown
-
2015
- 2015-09-09 US US14/848,452 patent/US20160002332A1/en not_active Abandoned
-
2017
- 2017-09-11 IL IL254416A patent/IL254416B/en active IP Right Grant
- 2017-09-28 US US15/719,220 patent/US10513557B2/en active Active
-
2019
- 2019-02-22 HR HRP20190358TT patent/HRP20190358T1/hr unknown
- 2019-02-27 CY CY20191100246T patent/CY1121368T1/el unknown
-
2021
- 2021-11-09 CY CY20211100968T patent/CY1124778T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12014501613A1 (en) | Anti-asic1 antibodies and uses thereof | |
MY167920A (en) | HUMAN ANTIBODIES TO GFRα3 AND METHODS OF USE THEREOF | |
PH12015501558A1 (en) | Human antibodies to respiratory syncytial virus f protein and methods of use thereof | |
NZ707086A (en) | Anti-cd40 antibodies and methods of use | |
UA115122C2 (uk) | Cd3-зв'язувальна молекула, здатна до зв'язування з cd3 людини і cd3, що не є людським | |
AU2011328009A8 (en) | Compounds and methods for treating pain | |
MX2015010749A (es) | Anticuerpos humanos para nav1.7. | |
WO2015009726A3 (en) | Medical uses of cd38 agonists | |
MX339239B (es) | Anticuerpos anti-cd40 y metodos de uso. | |
MX341578B (es) | Tratamiento de la osteoartritis y del dolor. | |
EA201390506A1 (ru) | Полипептиды, которые связывают компонент с5 комплемента человека | |
EA201591762A1 (ru) | Человеческие антитела к grem1 | |
PH12015502829A1 (en) | Lectin-like oxidized ldl receptor1 antibodies and methods of use | |
MX2015017853A (es) | Anticuerpos contra el receptor 1 de ldl oxidada tipo lectina de metodos de uso. | |
MX2015011518A (es) | Agentes de enlace de met y usos de los mismos. | |
MX2015008534A (es) | COMPOSICIONES DE ANTICUERPO ANTI-INTEGRINA ß1 Y METODOS DE USO DE LAS MISMAS. | |
MX2014001766A (es) | Anticuerpos de neuregulina y sus usos. | |
MX366046B (es) | Moléculas de unión que se adhieren al factor de complemento c2 humano y usos de los mismos. | |
MX2017001983A (es) | Agentes de union a proteina r-espondina 1 (rspo1) y usos de los mismos. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |